Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(tested or 100% immunogen sequence identity)
IHC (1 - 20 µg/ml)
Western blot (1 - 10 µg/ml)
ELISA (0.5 - 1 µg/ml)
Performing IHC? See our complete line of Immunohistochemistry Reagents including antigen retrieval solutions, blocking agents
ABC Detection Kits and polymers, biotinylated secondary antibodies, substrates and more.
SLC18A1 / VMAT1 antibody was raised against a 12 amino acid C-terminal peptide sequence from rat VMAT1 (1). This peptide is predicted to be cytoplasmic.
Detects a major band at ~55kD in postnuclear supernatants of CHO transfected with VMAT1 and not in wild type cells. Some additional bands, both higher and lower MW, were also detected and remain unaffected by the inclusion of protease inhibitors. Species Reactivity: Rat. Not expected to cross-react with human VMAT1.
Western blot: 1-10 ug/ml (Chemiluminescence technique) Immunohistochemistry: 1-20 ug/ml on paraformaldehyde fixed sections. ELISA: 0.5-1.0 ug/ml (1 ug/ml VMAT1 peptide/well).
PBS, pH 7.4, 0.1% BSA
Short term: 4°C. Long term: Store at -20°C. Avoid freeze-thaw cycles.
The vesicular monoamine transporter acts to accumulate cytosolic monoamines into vesicles, using the proton gradient maintained across the vesicular membrane. Its proper function is essential to the correct activity of the monoaminergic systems that have been implicated in several human neuropsychiatric disorders. The transporter is a site of action of important drugs, including reserpine and tetrabenazine (Peter et al., 1993 [PubMed 7905859]). See also SLC18A2 (MIM 193001).